Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients

Two-Drug Antiretroviral Regimens expert panel

Research output: Contribution to journalArticlepeer-review

Abstract

New strategies for HIV treatment able to reduce drug-exposure, medium-long term toxicities and costs are a recognized clinical need. The availability of newer drugs with improved potency and tolerability, as well as high genetic barrier to resistance, makes antiretroviral-sparing strategies with two-drug regimens (2DRs) particularly attractive. Substantial evidence has been generated over the last few years supporting 2DR in virologically suppressed HIV infected patients for whom a therapy switch is planned. More recently, very promising data on 2DR in naïve patients have also been reported. The main purpose of this consensus is to provide an overview of guideline indications and recommendations, and the most recent data from clinical studies of 2DR in both naïve and virologically suppressed patients. As an expert consensus, suggestions and indications on the use and management of 2DR are also provided.

Original languageEnglish
Pages (from-to)69-80
Number of pages12
JournalThe new microbiologica
Volume42
Issue number2
Publication statusPublished - Apr 1 2019

Keywords

  • Antiretroviral therapy
  • Dolutegravir
  • HIV
  • HIV drug-resistance
  • Two-drug regimens
  • Virological efficacy

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients'. Together they form a unique fingerprint.

Cite this